Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 4431

Sort by

Sort Order Select

Journal Articles

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

Blood (2021) 137 (8): 1019–1023.

https://doi.org/10.1182/blood.2020008164

Published: 2021

Includes: Supplemental data

Journal Articles

Cold agglutinin disease revisited: a multinational, observational study of 232 patients

Blood (2020) 136 (4): 480–488.

https://doi.org/10.1182/blood.2020005674

Published: 2020

Includes: Supplemental data

Journal Articles

Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report

Lauri M. Burroughs, Aleksandra Petrovic, Ruta Brazauskas, Xuerong Liu, Linda M. Griffith, Hans D. Ochs, Jack J. Bleesing, Stephanie Edwards, Christopher C. Dvorak, Sonali Chaudhury, Susan E. Prockop, Ralph Quinones, Frederick D. Goldman, Troy C. Quigg, Shanmuganathan Chandrakasan, Angela R. Smith, Suhag Parikh, Blachy J. Dávila Saldaña, Monica S. Thakar, Rachel Phelan, Shalini Shenoy, Lisa R. Forbes, Caridad Martinez, Deepak Chellapandian, Evan Shereck, Holly K. Miller, Neena Kapoor, Jessie L. Barnum, Hey Chong, David C. Shyr, Karin Chen, Rolla Abu-Arja, Ami J. Shah, Katja G. Weinacht, Theodore B. Moore, Avni Joshi, Kenneth B. DeSantes, Alfred P. Gillio, Geoffrey D. E. Cuvelier, Michael D. Keller, Jacob Rozmus, Troy Torgerson, Michael A. Pulsipher, Elie Haddad, Kathleen E. Sullivan, Brent R. Logan, Donald B. Kohn, Jennifer M. Puck, Luigi D. Notarangelo, Sung-Yun Pai, David J. Rawlings, Morton J. Cowan

Blood (2020) 135 (23): 2094–2105.

https://doi.org/10.1182/blood.2019002939

Published: 2020

Journal Articles

Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma

Blood (2019) 134 (Supplement_1): 4435.

https://doi.org/10.1182/blood-2019-126104

Published: 2019

Journal Articles

Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction Is Highly Effective in Young AML Patients with Concomitant NPM1 and FLT3-ITD Mutation Irrespectively of FLT3-ITD Allelic Burden

Blood (2019) 134 (Supplement_1): 3828.

https://doi.org/10.1182/blood-2019-131303

Published: 2019

Journal Articles

Early Follicular Lymphoma Progression in Patients Treated with Frontline Immunochemotherapy with/without Rituximab Maintenance: Clinically Meaningful Even in Chemosensitive Individuals

Vit K Prochazka, MD prof, David Belada, MD PhD, Andrea Janikova, MD PhD Assoc Prof, Katerina Benesova, MD PhD, Heidi Mocikova, MD PhD, Juraj Duras, MD, Robert Pytlik, MD PhD, Jan Pirnos, MD, Alice Sýkorová, MD PhD, Vit Campr, MD PhD, Jozef Michalka, MD, Kateřina Kopečková, MD PhD, Jitka Dlouha, Tomas Papajik, MD prof, Marek Trneny, MD prof

Blood (2019) 134 (Supplement_1): 3983.

https://doi.org/10.1182/blood-2019-129756

Published: 2019

Journal Articles

Mutational Profiling Predicts Clinical Outcomes to Azacytidine and Low Dose Cytarabine Plus Fludarabine (FLUGA) in Elderly Acute Myeloid Leukemia Patients Enrolled in the Pethema Phase III Flugaza Trial

Blood (2019) 134 (Supplement_1): 3891.

https://doi.org/10.1182/blood-2019-127187

Published: 2019

Journal Articles

A Phase 1/2 Study of Quizartinib (Q) in Combination with Re-Induction Chemotherapy and As Single-Agent Continuation Therapy in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

C. Michel Zwaan, MD PhD, Edward Anders Kolb, MD, Derek E. Mires, PharmD, Michele Vigliotti, PharmD, Jingdong Xie, PhD, Pamela Downs, BS, Arthur P DeCillis, MD MS, Cara A Rabik, MD PhD, Todd M Cooper, DO

Blood (2019) 134 (Supplement_1): 3937.

https://doi.org/10.1182/blood-2019-121736

Published: 2019

Journal Articles

Phase II Study of Midostaurin + Chemotherapy in Pediatric Patients with Untreated, Newly Diagnosed, FLT3 -Mutated Acute Myeloid Leukemia (AML)

Dirk Reinhardt, MD, Christian Michel Zwaan, Albert Hoenekopp, Julie Niolat, Sophie Ifrah, Florence Noel-Baron, Franco Locatelli, MD

Blood (2019) 134 (Supplement_1): 3835.

https://doi.org/10.1182/blood-2019-128043

Published: 2019

Journal Articles

Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3 -Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Cynthia Z. Qi, MBA, Bhavik J. Pandya, PharmD, Andy Garnham, Hongbo Yang, Manasee V Shah, MPH

Blood (2019) 134 (Supplement_1): 3859.

https://doi.org/10.1182/blood-2019-123819

Published: 2019

Journal Articles

Risk Adapted Therapeutic Strategy of Acute Myeloid Leukemia

Razan Mohty, MD, Radwan Massoud, BS, MD, Zaher Chakhachiro, MD, Rami Mahfouz, MD, Samer Nassif, MD, Jean Elcheikh, MD, Ali Bazarbachi, MD PhD

Blood (2019) 134 (Supplement_1): 3860.

https://doi.org/10.1182/blood-2019-125237

Published: 2019

Journal Articles

Interim Results from the Phase I Deplethink Trial Evaluating the Infusion of a NKG2D CAR T-Cell Therapy Post a Non-Myeloablative Conditioning in Relapse or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

A. Samer Al-Homsi, MD, Enkhtsetseg Purev, MD PhD, Philippe Lewalle, Maher Abdul-Hay, MD, Daniel A Pollyea, MD, Adriano Salaroli, MD, Thomas Lequertier, Erik Alcantar-Orozco, MD, Fabian Borghese, Caroline Lonez, PhD, Nathalie Braun, Florence Renard, Anne Flament, MD, Ine Moors, MD, Tessa Kerre

Blood (2019) 134 (Supplement_1): 3844.

https://doi.org/10.1182/blood-2019-128267

Published: 2019

Journal Articles

Successful Treatment of Chimeric Antigen Receptor T Cell Therapy in Refractory or Relapsed Acute Leukemia Patients with TP53 alterations

Changju Qu, PhD, Jia Yin, Liqing Kang, Zheng Li, Haiping Dai, Xiaming Zhu, Lei Yu, Depei Wu, MD PhD, Xiaowen Tang

Blood (2019) 134 (Supplement_1): 3822.

https://doi.org/10.1182/blood-2019-128013

Published: 2019

Journal Articles

Humanized CD19-Specific Chimeric Antigen Receptor T Cells for Acute Lymphoblastic Leukemia

Jiang Cao, MD, Hai Cheng, MD, Kunming Qi, Wei Chen, Ming Shi, Junnian Zheng, Kailin Xu, MD

Blood (2019) 134 (Supplement_1): 3872.

https://doi.org/10.1182/blood-2019-128286

Published: 2019

Journal Articles

Safety and Efficacy of Tisagenlecleucel (CTL019) in B-Cell Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults: The French Experience

Blood (2019) 134 (Supplement_1): 3876.

https://doi.org/10.1182/blood-2019-131123

Published: 2019

Journal Articles

Granulocyte Colony-Stimulating Factor (G-CSF) Interactions with Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma

Daria Gaut, MD, Kevin Tang, BS, BA, Myung Sim, PhD, Tuyen Duong, Joshua Sasine, MD PhD, Patricia A. Young, MD

Blood (2019) 134 (Supplement_1): 4109.

https://doi.org/10.1182/blood-2019-122195

Published: 2019

Journal Articles

Cellular Kinetics of CD19 Chimeric Antigen Receptor T Cells in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma

Caixia Li, Changfeng Zhang, PhD, Ying Zhang, Xiaoyan Lou, Jinfang Zhang, Jia Chen, MD, Xiaochen Chen, Liqing Kang, Jin Zhou, Xiangping Zong, Zhen Yang, Jiaqi Li, Wei Qi, Lei Yu, Depei Wu, MD PhD

Blood (2019) 134 (Supplement_1): 4097.

https://doi.org/10.1182/blood-2019-127928

Published: 2019

Journal Articles

Phase 1 Study of on Site Manufactured Anti-CD19 CAR-T Cells: Responses in Subjects with Rapidly Progressive Refractory Lymphomas

Blood (2019) 134 (Supplement_1): 4074.

https://doi.org/10.1182/blood-2019-131300

Published: 2019

Journal Articles

Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma

Blood (2019) 134 (Supplement_1): 4106.

https://doi.org/10.1182/blood-2019-127094

Published: 2019

Journal Articles

Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR-T Cell Therapy

Caron A. Jacobson, MD, Alex F. Herrera, MD, Lihua E Budde, MD PhD, Daniel J. DeAngelo, MD, Christopher Heery, MD, Anthony Stein, MD, Michael D. Jain, MD PhD, Bijal Shah, MD

Blood (2019) 134 (Supplement_1): 4107.

https://doi.org/10.1182/blood-2019-128203

Published: 2019

NARROW

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

Cold agglutinin disease revisited: a multinational, observational study of 232 patients

Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report

Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma

Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction Is Highly Effective in Young AML Patients with Concomitant NPM1 and FLT3-ITD Mutation Irrespectively of FLT3-ITD Allelic Burden

Early Follicular Lymphoma Progression in Patients Treated with Frontline Immunochemotherapy with/without Rituximab Maintenance: Clinically Meaningful Even in Chemosensitive Individuals

Mutational Profiling Predicts Clinical Outcomes to Azacytidine and Low Dose Cytarabine Plus Fludarabine (FLUGA) in Elderly Acute Myeloid Leukemia Patients Enrolled in the Pethema Phase III Flugaza Trial

A Phase 1/2 Study of Quizartinib (Q) in Combination with Re-Induction Chemotherapy and As Single-Agent Continuation Therapy in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

Phase II Study of Midostaurin + Chemotherapy in Pediatric Patients with Untreated, Newly Diagnosed, FLT3 -Mutated Acute Myeloid Leukemia (AML)

Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3 -Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Risk Adapted Therapeutic Strategy of Acute Myeloid Leukemia

Interim Results from the Phase I Deplethink Trial Evaluating the Infusion of a NKG2D CAR T-Cell Therapy Post a Non-Myeloablative Conditioning in Relapse or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Successful Treatment of Chimeric Antigen Receptor T Cell Therapy in Refractory or Relapsed Acute Leukemia Patients with TP53 alterations

Humanized CD19-Specific Chimeric Antigen Receptor T Cells for Acute Lymphoblastic Leukemia

Safety and Efficacy of Tisagenlecleucel (CTL019) in B-Cell Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults: The French Experience

Granulocyte Colony-Stimulating Factor (G-CSF) Interactions with Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma

Cellular Kinetics of CD19 Chimeric Antigen Receptor T Cells in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma

Phase 1 Study of on Site Manufactured Anti-CD19 CAR-T Cells: Responses in Subjects with Rapidly Progressive Refractory Lymphomas

Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma

Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR-T Cell Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only